Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 6, 2024

https://www.globenewswire.com/news-release/2024/05/06/2876127/24180/en/Celldex-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html

– Phase 3 CSU studies expected to initiate in summer 2024 –
– Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 –
– Enrollment completed in Phase 2 CIndU study; 12 week data expected 2H 2024 –
– Phase 2 PN study initiated; enrollment progressing in Phase 2 EoE study –
– Atopic dermatitis selected as next indication; Phase 2 study to initiate by YE 2024 –

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.